不同酶型耐碳青霉烯类肺炎克雷伯菌体外联合药敏研究

in vitro combined antimicrobial susceptibility study of carbapenem-resistant Klebsiella pneumoniae with different enzyme types

  • 摘要: 目的 探究耐碳青霉烯类肺炎克雷伯菌(CRKP)不同碳青霉烯酶型的体外联合药敏特征,重点关注头孢他啶/阿维巴坦(CZA)耐药、多黏菌素B(PB)耐药及混合酶型CRKP亚群,为临床精准治疗提供依据。方法 收集2023年1-12月河南省人民医院分离的147株CRKP,经胶体金免疫层析法鉴定为123株产肺炎克雷伯菌碳青霉烯酶的肺炎克雷伯菌(KPC-KP)、11株产新德里金属β-内酰胺酶的KP(NDM-KP)和13株产KPC-NDM酶的KP(KPC-NDM-KP),重点纳入PB耐药和CZA耐药菌株。采用棋盘微量稀释法测定CZA及PB分别与美罗培南(MEM)、氨曲南(ATM)、亚胺培南(IPM)、替加环素(TGC)等药物的联合效果,计算部分抑菌浓度指数(FICI)和敏感折点指数(SBPI)。结果 KPC-KP:CZA联合MEM、ATM、IPM的协同率(86.67%、87.01%和80.50%)高于CZA联合AMK、TGC组(P<0.05),CZA耐药CRKP结果与其一致; PB耐药株中PB联合CZA的协同率为54.00%,优于其他PB联合方案(P<0.05)。NDM-KP:CZA联合ATM的协同率为83.33%。KPC-NDM-KP:CZA联合ATM的协同/相加率为100.00%。结论 FICI与SBPI双指标体系为多重耐药CRKP感染的精准治疗提供了重要实验依据。本研究首次系统阐明针对CZA/PB耐药及混合酶型CRKP的联合用药规律:对CZA耐药的KPC-KP,推荐CZA联合β-内酰胺类药物; 对PB耐药的CRKP,PB联合CZA方案显著优于传统组合; 对KPC-NDM-KP,应首选CZA联合ATM。

     

    Abstract: OBJECTIVE To investigate the in vitro combined antimicrobial susceptibility characteristics of carbapenem-resistant Klebsiella pneumoniae (CRKP) with different carbapenemase types, with a focus on the subgroups of CRKP resistant to ceftazidime/avibactam (CZA), polymyxin B (PB) and those with mixed enzyme types, providing a basis for precise clinical treatment. METHODS A total of 147 CRKP strains isolated from Henan Provincial People's Hospital from Jan. to Dec. 2023 were collected. Among them, 123 strains were identified as K. pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP), 11 strains as New Delhi metallo-β-lactamase-producing KP (NDM-KP), and 13 strains as KPC-NDM-producing KP (KPC-NDM-KP) with the colloidal gold immunochromatography. Strains resistant to PB and CZA were particularly included. The combined effects of CZA and PB with drugs such as meropenem (MEM), aztreonam (ATM), imipenem (IPM) and tigecycline (TGC) were determined with the checkerboard microdilution method, and the fractional inhibitory concentration index (FICI) and susceptibility breakpoint index (SBPI) were calculated. RESULTS For KPC-KP: The synergistic rates of CZA combined with MEM, ATM and IPM (86.67%, 87.01% and 80.50%, respectively) were higher than those of CZA combined with amikacin (AMK) and TGC (P< 0.05), and the results for CZA-resistant CRKP were consistent with this. Among PB-resistant strains, the synergistic rate of PB combined with CZA was 54.00%, which was superior to other PB combination regimens (P< 0.05). For NDM-KP: The synergistic rate of CZA combined with ATM was 83.33%. For KPC-NDM-KP: The synergistic/additive rate of CZA combined with ATM was 100.00%. CONCLUSIONS The dual-index system of FICI and SBPI provides important experimental evidence for the precise treatment of multidrug-resistant CRKP infection. This study systematically elucidates, for the first time, the combined medication patterns for CZA/PB-resistant and mixed enzyme-type CRKP: for CZA-resistant KPC-KP, CZA combined with β-lactam drugs is recommended. For PB-resistant CRKP, the PB combined with CZA regimen is significantly superior to traditional combinations. For KPC-NDM-KP, CZA combined with ATM should be the first choice.

     

/

返回文章
返回